Repligen Corporation (RGEN)
| Market Cap | 7.25B |
| Revenue (ttm) | 738.26M |
| Net Income (ttm) | 48.89M |
| Shares Out | 56.33M |
| EPS (ttm) | 0.86 |
| PE Ratio | 149.69 |
| Forward PE | 65.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 830,718 |
| Open | 132.71 |
| Previous Close | 133.65 |
| Day's Range | 128.05 - 133.94 |
| 52-Week Range | 102.97 - 175.77 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 173.09 (+34.46%) |
| Earnings Date | Feb 24, 2026 |
About RGEN
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price target is $173.09, which is an increase of 34.46% from the latest price.
News
Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript
Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript
Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f...
Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profit...
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET
Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected...
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate i...
Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new hi...
Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Repligen Corporation to Present at Evercore Healthcare Conference
WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participat...
Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Repligen Corporation ( RGEN) 7th Annual Wolfe Research Healthcare Conference November 18, 2025 12:40 PM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Steven Chehames Confere...
Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Repligen Corporation ( RGEN) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Olivier Loeillot - President, CEO & Director Conference Call Participants M...
Repligen: Rare Growth In The Biopharma Supplies Industry
Repligen stands out as a leading bioprocess supplier, benefiting from secular growth in biologics and industry patent expirations. RGEN's strong balance sheet, recurring organic growth, and strategic ...
Repligen Corporation (RGEN) Presents at Stifel 2025 Healthcare Conference Transcript
Repligen Corporation ( RGEN) Stifel 2025 Healthcare Conference November 11, 2025 10:00 AM EST Company Participants Olivier Loeillot - President, CEO & Director Conference Call Participants Daniel Ari...
Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript
Repligen Corporation ( RGEN) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Jacob Johnson - Vice President of...
Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jacob Johnson Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compl...
Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its t...
Repligen to Report Third Quarter 2025 Financial Results
Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET
Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Repligen Corporation (NASDAQ:RGEN) Bank of America Global Healthcare Conference 2025 September 25, 2025 6:35 AM EDT Company Participants Olivier Loeillot - President, CEO & Director Jason Garland - C...
Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Repligen Corporation (NASDAQ:RGEN) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Olivier Loeillot - President, CEO & Director Jason Garland - C...
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
Repligen Corporation to Present at Upcoming September Conferences
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending ...
Repligen Corporation: Still Navigating Through The Covid Cliff
Repligen Corporation's Q2 results beat revenue expectations driven by strong revenue growth from consumables and biopharma sales. The company has diversified its product portfolio and customer base th...
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026
Repligen RGEN has been in a steady downtrend for over 1400 days. Adhishthana principles suggest the weakness is likely to continue.